Anhui Weiming Damu Biomedical Co., Ltd.

The main purpose of the trial is to compare the pharmacokinetic characteristics of a single subcutaneous injection of a recombinant anti-TNFα fully human monoclonal antibody injection and the original drug Adalimumab (Humira®) in healthy subjects, and to provide a basis for the design of later clinical trials. The secondary purpose of the trial is to observe the safety of a recombinant anti-TNFα fully human monoclonal antibody injection and the original drug Adalimumab (Humira®) in healthy subjects.